ID   HTR.B7-1/B7-2
AC   CVCL_C0DI
DR   Wikidata; Q112929782
RX   PubMed=8609411;
CC   Selected for resistance to: ChEBI; CHEBI_472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=MGI; MGI:101775; Cd80.
CC   Genetic integration: Method=Transfection/transduction; Gene=MGI; MGI:101773; Cd86.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; Q9QNF7; Human herpesvirus 1 TK.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21632; Mouse mast cell neoplasm
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_C0DG ! HTR.B7-1
SX   Male
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 6
//
RX   PubMed=8609411; DOI=10.4049/jimmunol.156.8.2909;
RA   Gajewski T.F., Fallarino F., Uyttenhove C., Boon T.;
RT   "Tumor rejection requires a CTLA4 ligand provided by the host or
RT   expressed on the tumor: superiority of B7-1 over B7-2 for active
RT   tumor immunization.";
RL   J. Immunol. 156:2909-2917(1996).
//